A Big Year for New HIV Prevention Choices

Craig W. Hendrix, MD
Wellcome Professor and Director, Division of Clinical Pharmacology
Departments of Medicine and Pharmacology
Johns Hopkins University School of Medicine, Baltimore, MD



CME VIDEOTop of page

About the Presenter:Top of page

Craig Hendrix trained in infectious diseases and clinical pharmacology at Hopkins before 10 years as an Air Force physician and 23 years at Johns Hopkins. Dr. Hendrix’s primary research focus is clinical pharmacology of HIV pre-exposure prophylaxis. He’s served as Principal Investigator of over 75 phase I clinical studies, mostly involving pre-exposure prophylaxis at Hopkins. He’s also served as principal pharmacologist for over 50 clinical trials in the Microbicide Trials Network and HIV Prevention Trials Network. He has published over 250 original scientific papers.

Learning Objectives: Top of page

At the completion of this educational session, learners will:

  • Describe the challenges to PrEP development.
  • Describe the challenges to PrEP implementation.
  • Discuss ongoing development of vaginal and rectal microbicides.
  • Discuss ongoing development of long-acting PrEP, including antiretrovirals and monoclonal antibodies.

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for October 14, 2020 as a live activity.  This activity will also be available as an enduring activity from October 15, 2020, through October 14, 2023.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity. - Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose. - Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. - Dr. Craig W. Hendrix (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research contract/Advisory board with Gilead, Merck, and ViiV; Founding partner of Priönde Biopharma. Dr. Hendrix will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Evaluation

You must be logged in to post a comment. Login | Register